LTR Pharma (ASX:LTP) Total Stockholders Equity: A$26.87 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
7 GF Score
Price A$0.48
View Full Analysis

What is LTR Pharma Total Stockholders Equity?

LTR Pharma ASX:LTP -3.06% 7 Total Stockholders Equity is A$26.87 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 7/100.

LTR Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$26.87 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. LTR Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. LTR Pharma's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.00.

LTR Pharma  (ASX:LTP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

LTR Pharma's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(26.865-0)/181.645
=0.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

LTR Pharma's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 26.865
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Stockholders Equity Related Terms

LTR Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Stockholders Equity Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
-0.04 1.77 7.49 2.94 31.51

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial 6.28 2.94 34.30 31.51 26.87
ASX:LTP
7GF Score
LTR Pharma Ltd ASX:LTP
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of A$26.87 Mil mean?
LTR Pharma (ASX:LTP) has a Total Stockholders Equity of A$26.87 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for LTR Pharma and its competitors.
Is LTR Pharma's Total Stockholders Equity too high?
LTR Pharma's current Total Stockholders Equity is A$26.87 Mil. Overall, LTR Pharma has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Total Stockholders Equity compare to VRTX and REGN?
LTR Pharma's Total Stockholders Equity of A$26.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for LTR Pharma and its competitors. LTR Pharma's current Total Stockholders Equity is A$26.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Total Stockholders Equity of A$26.87 Mil. The current Total Stockholders Equity is A$26.87 Mil. LTR Pharma's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Total Stockholders Equity is A$26.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
7GF Score

Get the complete analysis for ASX:LTP

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price